Bristol Myers Squibb (CELG-RI) Return on Capital Employed (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Return on Capital Employed of 4.05% for Q2 2026, up 743.0% year-over-year from 0.48% in Q2 2025, and up 40.82% quarter-over-quarter from 6.84% in Q1 2026.
Bristol Myers Squibb (CELG-RI) Return on Capital Employed (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Return on Capital Employed for 17 consecutive years, with 4.05% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 743.0% year-over-year to 4.05%; the TTM figure through Jun 2026 stood at 4.05% (up 743.0% YoY), while the FY2025 annual figure was 6.79%, up 2509.0% from the prior year.
- Return on Capital Employed rose to 4.05% in Q2 2026 per CELG-RI's latest filing, from 6.84% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1.88% in Q1 2023 and bottomed at 32.22% in Q4 2024.
- Historically, Return on Capital Employed has averaged 9.91% across 5 years, with a median of 5.31% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 2904 bps — and 2025, when it surged 2564 bps.
- Bristol Myers Squibb's Return on Capital Employed stood at 3.21% in 2022, then increased by 1 bps to 3.18% in 2023, then slumped by 915 bps to 32.22% in 2024, then jumped by 80 bps to 6.58% in 2025, then surged by 38 bps to 4.05% in 2026.
- Business Quant data shows CELG-RI's Return on Capital Employed at 4.05% in Q2 2026, 6.84% in Q1 2026, and 6.58% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -4.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.05% |
| Mar 31, 2026 | -6.84% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -9.78% |
| Jun 30, 2025 | -11.48% |
| Mar 31, 2025 | -11.63% |
| Dec 31, 2024 | -32.22% |
| Sep 30, 2024 | -26.26% |
| Jun 30, 2024 | -24.29% |
| Mar 31, 2024 | -23.72% |
| Dec 31, 2023 | -3.18% |
| Sep 30, 2023 | -2.78% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | -1.88% |
| Dec 31, 2022 | -3.21% |
| Sep 30, 2022 | -2.72% |
| Jun 30, 2022 | -2.70% |
| Mar 31, 2022 | -2.78% |
| Dec 31, 2021 | -2.09% |
| Sep 30, 2021 | -16.45% |